4-Hexyl-1,3-phenylenediol, a nuclear factor-κB inhibitor, improves photodamaged skin and clinical signs of ageing in a double-blinded, randomized controlled trial

Br J Dermatol. 2015 Jul;173(1):218-26. doi: 10.1111/bjd.13747. Epub 2015 Jun 11.

Abstract

Background: The nuclear factor-κB (NF-κB) pathway is a key mediator of inflammation; however, few studies have examined the direct effects of NF-κB inhibition on the skin.

Objectives: To investigate NF-κB activity in cultured human fibroblasts and to investigate the effects of 4-hexyl-1,3-phenylenediol (an NF-κB inhibitor) on elastin and collagen gene expression in vitro and on the clinical appearance of photodamaged skin.

Methods: The amount and activity of NF-κB in human fibroblasts obtained from donors (17-78 years old) was measured after transfection with a NF-κB reporter and a luciferase promoter system. The expression of extracellular matrix (ECM) genes was determined using quantitative polymerase chain reaction. Women with moderate skin photodamage were randomized to daily treatment with a topical lotion containing 4-hexyl-1,3-phenylenediol (n = 30) or vehicle (n = 29) for 8 weeks, with clinical assessments at baseline and weeks 2, 4 and 8.

Results: Fibroblasts obtained from donors older than 50 years had higher NF-κB activity compared with cells from younger donors; inhibition of the NF-κB pathway with 4-hexyl-1,3-phenylenediol enhanced the expression of ECM genes. In women, treatment for 8 weeks with 4-hexyl-1,3-phenylenediol significantly improved crow's feet fine lines, cheek wrinkles, age spots, mottled pigmentation and radiance compared with both the vehicle and baseline. Furthermore, treatment with 4-hexyl-1,3-phenylenediol resulted in a twofold greater clinical improvement in overall photodamage compared with the vehicle group.

Conclusions: Inhibition of the proinflammatory NF-κB pathway resulted in increased expression of ECM proteins in vitro and significant clinical improvement in photodamaged skin.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Cells, Cultured
  • Collagen Type I / metabolism
  • Dermatologic Agents / administration & dosage*
  • Double-Blind Method
  • Enzyme-Linked Immunosorbent Assay
  • Facial Dermatoses / drug therapy*
  • Female
  • Fibroblasts / drug effects
  • Humans
  • In Vitro Techniques
  • Middle Aged
  • NF-kappa B / antagonists & inhibitors*
  • Photosensitivity Disorders / drug therapy*
  • Resorcinols / administration & dosage*
  • Skin Aging / drug effects*
  • Treatment Outcome
  • Young Adult

Substances

  • 4-hexyl-1,3-phenylenediol
  • Collagen Type I
  • Dermatologic Agents
  • NF-kappa B
  • Resorcinols